News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novo Nordisk A/S (NVO) Reports Positive Results From First Phase 3 Trial With Long-Acting Factor IX for Treatment of Hemophilia B


5/17/2013 10:18:53 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BAGSVAERD, DENMARK--(Marketwired - May 17, 2013) - Novo Nordisk today announced the completion of paradigm™ 2, the first phase 3 trial with a long-acting FIX derivative, N9-GP (glycopegylated recombinant factor IX), for haemophilia B patients. Paradigm™ 2 is a multi-centre, blinded trial evaluating the safety and efficacy of N9-GP when used for on-demand or prophylactic treatment in patients with haemophilia B.

Company announcement No 37 / 2013: http://hugin.info/2013/R/1702902/562797.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE

[HUG#1702902]


Further information

Media:

Mike Rulis
+45 3079 3573
Email Contact

Ken Inchausti (US)
+1 609 514 8316
Email Contact

Investors:
Kasper Roseeuw Poulsen
+45 4442 4303
Email Contact

Frank Daniel Mersebach
+45 4442 0604
Email Contact

Lars Borup Jacobsen
+45 3075 3479
Email Contact

Jannick Lindegaard (US)
+1 609 786 4575
Email Contact



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES